Brief: Mendus To Report Positive Clinical And Preclinical Data In Ovarian Cancer At ESGO 2022 Congress

Mendus AB (publ)

17/10/2022 07:36

Oct 17 (Reuters) - Mendus AB (publ)  IMMUN.ST :
    * INITIAL DATA DEMONSTRATES THAT DCP-001 WAS SAFE AND
WELL-TOLERATED, CONFIRMING BENIGN SAFETY PROFILE OF DCP-001
OBSERVED IN MULTIPLE COMPLETED AND ONGOING CLINICAL TRIALS
    * PRESENTATION AT ESGO CONGRESS WILL ALSO INCLUDE NEW
PRECLINICAL
DATA DEMONSTRATING SYNERGISTIC EFFECTS OF COMBINING DCP-001
VACCINATION WITH INTRATUMORAL IMMUNE PRIMING
    * WE ALSO LOOK FORWARD TO REPORTING ADDITIONAL DATA IN
COMING
MONTHS FROM OUR OVARIAN CANCER PROGRAM

Source text for Eikon:  ID:nGNE6CFzwQ 
Further company coverage:  IMMUN.ST 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))